There are currently 12 active clinical trials seeking participants for Diabetic Macular Edema research studies. The states with the highest number of trials for Diabetic Macular Edema participants are Texas, California, Florida and Maryland.
Assessment of Retinal Fundus Imaging Camera
NCT06173232
Recruiting
The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy per ETDRS level 35 and higher with or without macular edema.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
12/07/2023
Locations: Midwest Eye Center, Cincinnati, Ohio
Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Register for Updates
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926
Recruiting
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\]... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Retinal Research Institute, LLC, Phoenix, Arizona +241 locations
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Register for Updates
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME
NCT04108156
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main Study, GR40550. Up to 100 participants from the main study will b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Barnet Dulaney Perkins Eye Center, Mesa, Arizona +91 locations
Conditions: Diabetic Macular Edema
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922
Recruiting
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Barnet Dulaney Perkins Eye Center, Phoenix, Arizona +47 locations
Conditions: Diabetic Macular Edema
Register for Updates
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854
Recruiting
This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Retinal Consultants of AZ, Ltd, Peoria, Arizona +13 locations
Conditions: Diabetic Macular Edema
Register for Updates
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
NCT06942520
Recruiting
Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
Gender:
ALL
Ages:
Between 25 years and 89 years
Trial Updated:
04/16/2025
Locations: Sierra Eye Associates, Reno, Nevada
Conditions: Diabetic Macular Edema
Register for Updates
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
NCT05802329
Recruiting
A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Advanced Research LLC, Deerfield Beach, Florida +4 locations
Conditions: Center Involved Diabetic Macular Edema, Diabetic Macular Edema
Register for Updates
Evaluation of K9 in Subjects with Diabetic Macular Edema (DME)
NCT06781255
Recruiting
A non-randomized study evaluating the safety of an orally administered inflammasome inhibitor, K9, for the treatment of diabetic macular edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Diabetic Macular Edema
Register for Updates
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
NCT06536491
Recruiting
This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/19/2025
Locations: Retina Associates of Florida, LLC, Tampa, Florida
Conditions: Diabetic Macular Edema
Register for Updates
4D-150 in Patients With Diabetic Macular Edema
NCT05930561
Recruiting
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Retinal Research Institute LLC, Phoenix, Arizona +14 locations
Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Register for Updates
Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema (DIAMOND-1)
NCT05066997
Recruiting
The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/14/2024
Locations: Oculis Investigative Site: University Retina - Lemont, Lemont, Illinois
Conditions: Diabetic Macular Edema
Register for Updates
Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema (DIAMOND-2)
NCT06172257
Recruiting
The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/31/2024
Locations: Oculis Investigative Site - Stanford Byers Eye Institute, Palo Alto, California
Conditions: Diabetic Macular Edema
Register for Updates